Clinical Technology Expert and Experienced Neuroscientist Join C-Path in Executive Director Roles

Scottie Kern and Dr. Terina N. Martínez Will Both Serve in Dual Positions

TUCSON, Ariz., June 24, 2021 — Critical Path Institute (C-Path) today announced it has named Scottie Kern, as both Executive Director of the Electronic Patient-Reported Outcome (ePRO) Consortium and Associate Director of the Patient-Reported Outcome (PRO) Consortium and Terina N. Martínez, Ph.D., as Executive Director of both the Duchenne Regulatory Science Consortium (D-RSC) and Critical Path to Therapeutics for the Ataxias (CPTA).Continue reading

C-Path Welcomes Alphabet Clinical Policy and Strategy Head, Former FDA Commissioner to Board

C-Path Announces Accelerated Data Sharing Collaboration with Tufts Medical Center

FDA Grant Supports Use of Real-World Data to Generate Real-World Evidence in Neonates

TUCSON, Ariz., May 12, 2021 — Critical Path Institute (C-Path) and Tufts Medical Center have announced a joint venture to integrate the first patient-level clinical trial data to generate actionable real-world evidence (RWE) for neonatal drug development, from real-world neonate data (RWD). This activity, funded by a grant from the U.S. Food and Drug Administration (FDA), is being executed through a neonatal pilot project within C-Path’s International Neonatal Consortium (INC). The data sharing collaboration and transfer also marks the fastest on record for C-Path — starting with the Data Contribution Agreement negotiations and receipt of the data in three months’ time this March.Continue reading

C-Path Appoints Quantitative Sciences Expert as New Sr. Vice President

Dr. Jeff Barrett will lead C-Path’s RDCA-DAP initiative focusing on rare disease data sharing and accelerating therapy development.

TUCSON, Ariz. May 6, 2021 — Critical Path Institute (C-Path) today announced the appointment of Jeff Barrett, Ph.D., F.C.P., as Senior Vice President and lead for its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) initiative.Continue reading

C-Path Opens Access to Duchenne Regulatory Science Consortium Database

Database will allow sharing of individual-level data with the goal of accelerating therapy development for Duchenne muscular dystrophy

TUCSON, Ariz., April 22, 2021 — Critical Path Institute (C-Path) announced today that it will open access to the Duchenne Regulatory Science Consortium (D-RSC) database to qualified researchers, through its Rare Disease Cures Accelerator, Data and Analytics Platform (RDCA-DAP®). The D-RSC database includes data from Duchenne muscular dystrophy (DMD) clinical trials, natural history studies and clinical data collections. The contributors of these datasets have given permission for this data to be shared externally to accelerate therapy development for DMD.

Continue reading